Palleon Announces NMPA IND Clearance for Phase 2 Trial of E-602
Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced that the China National Medical Products Administration (NMPA) has...